Brief: JW Therapeutics Announces NMPA Acceptance Of Supplemental New Drug Application For Carteyva In Patients With Follicular Lymphoma
27/02/2022 10:42
Feb 27 (Reuters) -
* JW THERAPEUTICS - ANNOUNCES NMPA ACCEPTANCE OF
SUPPLEMENTAL NEW
DRUG APPLICATION FOR CARTEYVA IN PATIENTS WITH FOLLICULAR
LYMPHOMA
Source text for Eikon: ID:nPn6yyVH1a
Further company coverage: 2126.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License